Article By:
Moon Kil Woong
Tuesday, July 27, 2021 9:01 AM EDT
PLX was up on FDA notice last year on a CRL postponement that its PDUFA review of PRX-102. In the meantime, phase III trials continue to provide more positive results. It is a stock worth watching.